Lyra Therapeutics (LYRA) FCF Margin (2021 - 2025)

Lyra Therapeutics has reported FCF Margin for 5 years, with the latest figure at 87357.14% in Q4 2025.

• On a quarterly basis, FCF Margin fell 8195332.0% year-over-year to 87357.14% in Q4 2025; TTM through Dec 2025 was 7275.13%, a 255876.0% decrease from a year earlier, with the FY2025 full-year figure at 7280.15%, down 256379.0% from the prior year.
• FCF Margin was 87357.14% for Q4 2025 at Lyra Therapeutics, down from 29632.0% in the prior quarter.
• The five-year high for FCF Margin was 1616.0% in Q2 2022, with the low at 110836.36% in Q4 2022.
• Average FCF Margin over 5 years is 20576.23%, with a median of 4596.54% recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: FCF Margin tumbled 10626810 bps in 2022, then jumped 9724390 bps in 2023.
• Over 5 years, FCF Margin stood at 4568.27% in 2021, then plunged by 2326 bps to 110836.36% in 2022, then jumped by 88 bps to 13592.47% in 2023, then surged by 60 bps to 5403.83% in 2024, then sank by 1517 bps to 87357.14% in 2025.
• The last three FCF Margin figures came in at 87357.14% (Q4 2025), 29632.0% (Q3 2025), and 3601.09% (Q2 2025), per Business Quant data.